{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:41:11Z","timestamp":1784126471199,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ebiom.2022.104376","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:58:27Z","timestamp":1669298307000},"page":"104376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study"],"prefix":"10.1016","volume":"86","author":[{"given":"Ipos","family":"Ngay Lukusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Van Reet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieudonn\u00e9","family":"Mumba Ngoyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick","family":"Mwamba Miaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Masumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pati","family":"Patient Pyana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried","family":"Mutombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digas","family":"Ngolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Kobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Akwaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9dard","family":"Ilunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Kaninda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Mutanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieudonn\u00e9","family":"Mpoyi Muamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Valverde Mordt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Tarral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Rembry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"B\u00fcscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-0962","authenticated-orcid":false,"given":"Veerle","family":"Lejon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104376_bib1","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human African trypanosomiasis","volume":"390","author":"B\u00fcscher","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104376_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S39728","article-title":"Epidemiology of human African trypanosomiasis","volume":"6","author":"Simarro","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.ebiom.2022.104376_bib3","series-title":"Control and surveillance of human African trypanosomiasis: report of a WHO Expert Committee","year":"2013"},{"key":"10.1016\/j.ebiom.2022.104376_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104376_bib5","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0140-6736(17)32758-7","article-title":"Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial","volume":"391","author":"Mesu","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104376_bib7","first-page":"93","article-title":"Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis","volume":"3","author":"Franco","year":"2012","journal-title":"Res Rep Trop Med"},{"key":"10.1016\/j.ebiom.2022.104376_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: M\u00e9decins Sans Fronti\u00e8res experience in the Democratic Republic of the Congo","volume":"56","author":"Alirol","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009903","article-title":"Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study","volume":"15","author":"Kuemmerle","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib10","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pt.2017.11.008","article-title":"Do cryptic reservoirs threaten gambiense-sleeping sickness elimination?","volume":"34","author":"B\u00fcscher","year":"2018","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ebiom.2022.104376_bib11","first-page":"362","volume":"95","author":"Miezan","year":"2002","journal-title":"Bull Soc Pathol Exot"},{"key":"10.1016\/j.ebiom.2022.104376_bib12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-3156.2005.01403.x","article-title":"Review article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up","volume":"10","author":"Lejon","year":"2005","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.ebiom.2022.104376_bib13","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-3156.2009.02248.x","article-title":"Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis","volume":"14","author":"Mumba Ngoyi","year":"2009","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.ebiom.2022.104376_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1086\/588668","article-title":"Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis","volume":"47","author":"Lejon","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002088","article-title":"Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness","volume":"7","author":"Tiberti","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1086\/649917","article-title":"How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness","volume":"201","author":"Mumba Ngoyi","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001662","article-title":"Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis","volume":"6","author":"Priotto","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib18","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1371\/journal.pntd.0000972","article-title":"Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study","volume":"5","author":"Deborggraeve","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jmoldx.2014.02.006","article-title":"Diagnosis of trypanosomatid infections","volume":"16","author":"Gonz\u00e1lez-Andrade","year":"2014","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.ebiom.2022.104376_bib20","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/infdis\/jiv337","article-title":"Trypanosoma brucei gambiense spliced leader RNA is a more specific marker for cure of human African trypanosomiasis than T.b. gambiense DNA","volume":"212","author":"Ilboudo","year":"2015","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009739","article-title":"Trypanosome SL-RNA detection in blood and cerebrospinal fluid to demonstrate active gambiense human African trypanosomiasis infection","volume":"15","author":"Ngay Lukusa","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib22","article-title":"Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2\/3 trial","author":"Kande Betu Kumeso","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib23","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1073\/pnas.1807915115","article-title":"Clinical and veterinary trypanocidal benzoxaboroles target CPSF3","volume":"115","author":"Wall","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ebiom.2022.104376_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr1259","article-title":"Correction of RT\u2013qPCR data for genomic DNA-derived signals with ValidPrime","volume":"40","author":"Laurell","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ebiom.2022.104376_bib25","series-title":"Human African trypanosomiasis: update of the methodological framework for clinical trials: report of the first meeting of the development of new tools subgroup","year":"2015"},{"key":"10.1016\/j.ebiom.2022.104376_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010047","article-title":"The elimination of human\u00a0African trypanosomiasis: achievements in relation to WHO road map targets for 2020","volume":"16","author":"Franco","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1086\/510534","article-title":"Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness","volume":"195","author":"Bisser","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/mmi.12764","article-title":"Transcriptome-wide analysis of trypanosome mRNA decay reveals complex degradation kinetics and suggests a role for co-transcriptional degradation in determining mRNA levels: transcriptome-wide mRNA decay in trypanosomes","volume":"94","author":"Fadda","year":"2014","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.ebiom.2022.104376_bib29","doi-asserted-by":"crossref","first-page":"e1151","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis","volume":"5","author":"Jacobs","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41564-018-0295-3","article-title":"REASSURED diagnostics to inform disease control strategies, strengthen health systems and improve patient outcomes","volume":"4","author":"Land","year":"2019","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ebiom.2022.104376_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12985-020-01435-6","article-title":"Rapid point-of-care detection of SARS-CoV-2 using reverse transcription loop-mediated isothermal amplification (RT-LAMP)","volume":"17","author":"Mautner","year":"2020","journal-title":"Virol J"},{"key":"10.1016\/j.ebiom.2022.104376_bib32","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.44.30053","article-title":"Development and deployment of a rapid recombinase polymerase amplification Ebola virus detection assay in Guinea in 2015","volume":"20","author":"Faye","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ebiom.2022.104376_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00216-017-0689-8","article-title":"Continuous-flow, microfluidic, qRT-PCR system for RNA virus detection","volume":"410","author":"Fern\u00e1ndez-Carballo","year":"2018","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.ebiom.2022.104376_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/JCM.02724-15","article-title":"Comparative evaluation of the diagnostic performance of the prototype Cepheid GeneXpert Ebola assay","volume":"54","author":"Jansen van Vuren","year":"2016","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ebiom.2022.104376_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007189","article-title":"Parasite specific 7SL-derived small RNA is an effective target for diagnosis of active\u00a0trypanosomiasis infection","volume":"13","author":"Chiweshe","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ebiom.2022.104376_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104308","article-title":"SHERLOCK4HAT: a CRISPR-based tool kit for diagnosis of human African trypanosomiasis","volume":"85","author":"Sima","year":"2022","journal-title":"eBioMedicine"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005588?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005588?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:23:56Z","timestamp":1762457036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422005588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"alternative-id":["S2352396422005588"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104376","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104376"}}